New study links genetic diversity of tumors with resistance to treatment in Asian lung cancer patients

February 13, 2018, Agency for Science, Technology and Research (A*STAR), Singapore
New study links genetic diversity of tumours with resistance to treatment in asian lung cancer patients
Researchers from Singapore discovered that the EGFR mutant lung cancer in Asians is more varied than its counterpart observed in Caucasians. This suggests that genetic evolution is driving lung cancers into two groups differentiated by patients’ ethnicities. Credit: A*STAR’s Genome Institute of Singapore

Scientists from A*STAR's Genome Institute of Singapore (GIS) and medical oncologists from the National Cancer Centre Singapore (NCCS) have discovered that lung cancer tumours in Asian patients contain much higher genetic diversity than previously expected. Hence, this type of tumour tends to develop resistance despite initial tumour shrinkage. With this discovery, scientists and oncologists are better equipped to guide treatments and develop more refined and personalised approaches to common non-small-cell lung carcinoma (NSCLC). The study was published in the international journal Nature Communications.

Lung cancer is the most common cause of cancer mortality in the world. It accounts for approximately 19 percent of all cancer-related deaths worldwide and has a mortality rate more than twice that of any other cancer. Lung cancer is also the most common type of cancer in Asia2. The number of incidences and deaths are expected to rise with increased pollution, particularly in large, densely populated Asian cities. Thus, newer and more effective individualised treatment strategies are crucial to tackle the growing threat and improve the quality of ' lives.

Lung cancer in Asian patients is characterised by an important mutation in a gatekeeper gene known as the epidermal growth factor receptor, EGFR3. Gatekeeper genes, also known as the , control and regulate cell cycles. It was discovered that mutations in this gene occur in more than 50 percent of the tumours in Singaporean patients. While drugs targeting it are effective in controlling the disease, the response is short-lived. Most patients eventually succumb to cancer relapse in a matter of months or a few years. In some instances, patients do not even respond to these drugs at all. The variability in clinical outcomes, and the tumours' seemingly inevitable development of resistance to treatment, have intrigued doctors for years, and have remained major stumbling blocks in administering better patient care.

"This joint study is one of the first major efforts to characterise and identify lung tumours in Singaporean patients on a large scale. It has generated a treasure trove of new genetic information and enabled us to perform detailed analyses, leading us to conclude that lung tumours in Asian patients are surprisingly more complex than previously appreciated," mentioned Dr. Rahul Nahar, the first author of this study and a Research Associate at GIS.

"The study of the genetic complexity of tumours in Asian patients has provided us with new insights as to why they may quickly develop resistance after initial response to anti-EGFR drug inhibitors. We also found that tumours with a high number of drivers, mutations that cause cancer progression, tend to be associated with poor drug response," explained Dr. Axel Hillmer, Principal Investigator at GIS and a co-corresponding author of this study.

"Understanding the comprehensive genetic landscape of these tumours allows us to go beyond single gene mutations (such as EGFR) to better understand the behaviour of individual tumours, and tailor treatments more effectively. Further work needs to be focused on identifying drug combinations or strategies that take into account the tumours' ability to adapt to different treatments," said Dr. Daniel Tan, Senior Consultant Medical Oncologist at NCCS and the corresponding author of this paper.

Professor Ng Huck Hui, Executive Director of GIS, said, "Timely and comprehensive research on disease states is critical, especially for diseases with a mortality rate as high as . The study represents one of the first attempts at such an in-depth analysis of this unique subtype of NSCLC, and has yielded new insights and research directions. Discoveries like this will continue to pave the way for developing increasingly precise treatments."

Explore further: Scientists reveal that new combination of clinically tested drugs inhibits growth of lung tumors

More information: Rahul Nahar et al. Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing, Nature Communications (2018). DOI: 10.1038/s41467-017-02584-z

Related Stories

Scientists reveal that new combination of clinically tested drugs inhibits growth of lung tumors

September 8, 2017
Research at the University of Southern Denmark has revealed that a new combination of clinically tested drugs inhibits the growth of tumours, thereby potentially improving patients' survival.

A new strategy induces the regression of advanced lung tumors in mice

January 25, 2018
A study published in Cancer Cell by researchers of the Molecular Oncology Program at the Spanish National Cancer Research Centre (CNIO) shows that the elimination of the c-Raf kinase by genetic manipulation causes the regression ...

Researchers show aspirin added to cancer drug improves effectiveness

December 4, 2017
Adding aspirin to some existing cancer drugs could increase their effectiveness against a group of tumours resistant to treatment, new research has shown.

New use for alcohol aversion drug in treatment of chemo resistant lung cancer found

October 4, 2017
Scientists have had positive results from a laboratory-based study using a well-known alcohol aversion drug to try to combat chemotherapy resistance in the most common type of lung cancer, non-small cell lung cancer (NSCLC). ...

A new way to diagnose and treat lung cancer

July 12, 2016
A team of researchers from Singapore has discovered a class of small RNA molecules, known as oncomiRs, which are responsible for fuelling lung cancer. Published in Nature Communications, the findings provide fresh insight ...

Mutations unveiled that predispose lung cancers to refractory histologic transformation

June 7, 2017
Cancer pedigree analysis reveals the mutations in RB1 and TP53 genes play a key role in treatment-resistant, cancer cell-type transformation during EGFR inhibitor therapy for lung cancers.

Recommended for you

Revealing the molecular mystery of human liver cells

October 22, 2018
A map of the cells in the human liver has been created by University Health Network Transplant Program and University of Toronto researchers, revealing for the first time differences between individual cells at the molecular ...

New tool gives deeper understanding of glioblastoma

October 22, 2018
Researchers in the lab of Charles Danko at the Baker Institute for Animal Health have developed a new tool to study genetic "switches" active in glioblastoma tumors that drive growth of the cancer. In a new paper in Nature ...

RNA thought to spread cancer shows ability to suppress breast cancer metastasis

October 22, 2018
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) appears to suppress breast cancer metastasis in mice, ...

New drug combination destroys chemo-resistant blood cancer

October 22, 2018
Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia (AML) and a diagnostic test to determine which AML patients ...

Targeting a hunger hormone to treat obesity

October 22, 2018
About 64 per cent of Canadian adults are overweight or obese, according to Health Canada. That's a problem, because obesity promotes the emergence of chronic diseases such as type 2 diabetes, heart disease and some cancers.

Major trial shows targeted drug extends breast cancer survival

October 22, 2018
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.